GTHX - G1 Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

30.35M

Cash

104.2M

Avg Qtr Burn

-16.71M

Short % of Float

5.96%

Insider Ownership

10.55%

Institutional Own.

44.36%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details Cancer, Solid tumor/s, Small cell lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Cancer, Breast cancer, Triple-negative breast cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) + avelumab Details Solid tumor/s, Cancer, Bladder cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) + antibody-drug conjugate (ADC), Trodelvy® (sacituzumab govitecan-hziy) Details Solid tumor/s, Cancer, Breast cancer, Triple-negative breast cancer , Metastatic breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rintodestrant + palbociclib Details Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trilaciclib (Cosela) (CDK4/6 inhibitor) Details Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.